. 2012 Jul 16;33(8):1085–1094. doi: 10.1038/aps.2012.65

Table 3. Steady-state pharmacokinetic parameters of CMAB001 following multiple dose subcutaneous administration of 1.0 mg/kg in patients with chronic plaque psoriasis (n=10). AUC_ss, represents observed AUC_0–z after the last dose at steady-state.

Parameters	C_{min ss} (μg·mL⁻¹)	C_{max ss} (μg·mL⁻¹)	C_avg (μg·mL⁻¹)	AUC_ss (μg·mL⁻¹)	Fluctuation %	Accumulation_index
1	7.488	10.984	8.685	60.797	40.25	2.09
2	5.025	6.911	5.976	41.835	31.55	2.14
3	5.245	7.361	6.381	44.667	33.16	2.26
4	2.902	5.106	4.350	30.447	50.67	2.29
5	3.019	4.973	4.258	29.804	45.90	2.18
6	3.957	5.961	5.098	35.683	39.31	2.34
7	3.114	5.362	4.649	32.540	48.36	2.03
8	2.835	4.667	3.908	27.357	46.86	2.25
9	4.091	5.814	5.043	35.300	34.16	2.29
10	5.086	6.722	5.854	40.977	27.93	2.19
mean	4.276	6.386	5.420	37.941	39.82	2.21
SD	1.472	1.845	1.403	9.819	7.91	0.10

Table 3. Steady-state pharmacokinetic parameters of CMAB001 following multiple dose subcutaneous administration of 1.0 mg/kg in patients with chronic plaque psoriasis (n=10). AUCss, represents observed AUC0–z after the last dose at steady-state.